ConcertAI Launches Agentic AI to Accelerate Clinical Trials

ConcertAI has launched Accelerated Clinical Trials (ACT), an enterprise agentic AI platform designed to automate and optimize the entire clinical trial lifecycle. Unveiled at SCOPE 2026 in Orlando, ACT integrates real-world data and proprietary datasets with advanced AI workflows to help sponsors and contract research organizations shorten trial timelines by 10 to 20 months, reduce costs, and bring therapies to patients faster.

Clinical trials are increasingly burdened by recruitment challenges, complex protocols, and fragmented data, often leading to costly amendments mid-study. ConcertAI says ACT addresses these inefficiencies by transforming trial operations into a unified, predictive system. Using AI-driven probability forecasting, the platform helps teams design trials that are more likely to meet enrollment targets and succeed without disruptive changes. CEO Eron Kelly said sponsors need an end-to-end solution that identifies bottlenecks and guides next actions—not another standalone tool.

ACT is built on CARAai™, ConcertAI’s proprietary agentic AI platform, and deploys specialized AI agents to automate key trial activities including literature review, protocol design, feasibility analysis, site selection, competitive trial assessment, and patient matching. According to ConcertAI, ACT can reduce study design timelines by up to 50% and cut protocol amendments by a similar margin through early AI-based validation. On the operational side, automated site activation and recruitment workflows can shorten timelines by 25–50%. The platform integrates with sources like PubMed and ClinicalTrials.gov and connects with existing trial systems to fit into current workflows.

Industry analysts have recognized ConcertAI for its applied use of generative and agentic AI in oncology trials, noting its ability to precisely match patients to studies while addressing protocol design challenges that historically relied on manual EMR analysis.